期刊文献+

眼表重建术后局部应用FK-506的初步临床观察 被引量:5

Priliminary clinical observation of topical use of FK 506 after ocular surface reconstruction
下载PDF
导出
摘要 目的 寻找眼表重建术后主要并发症的有效治疗措施。方法 对 32例 32只严重化学伤患眼施眼表重建术 (板层角膜移植、角膜缘移植及羊膜移植术 ) ,随机将研究对象分为治疗组及对照组 (各 16只眼 ) ;治疗组于术后 1wk局部应用 0 .5 g· L- 1的 FK- 5 0 6滴眼液 ,对照组应用 10 g· L- 1 Cs A滴眼液 ,观察 2组角膜新生血管指数、移植组织的排斥反应指数。结果 在随访期内 ,治疗组的组织排斥反应时间、发生率、角膜假性胬肉及睑球粘连 4个指标均明显优于对照组。结论 局部应用 FK- 5 0 6可有效提高眼表重建术的成功率。 Objective To find out effective treatments for complications after ocular surface reconstruction. Methods Lamellar keratoplasty, limbal stem cell and human amniotic membrane transplantation were performed on 32 patients(32 eyes) suffering from severe chemical burns, who were divided into the therapeutic group (16 eyes)and control group(16 eyes)randomly. While they were given the same routine treatment with cortisone, the therapeutic group and the control group received additional ophthalmic solution with FK 506(0.5g·L -1 ) and 10g·L -1 CsA in the same time respectively. The rejection indexs of transplanted tissue were observed. Results In follow up period the therapeutic group was significantly better than control group in graft rejection and prognosis. Conclusion The local applying of FK 506 can improve the rate of success in ocular surface reconstruction greatly.
出处 《眼科新进展》 CAS 2000年第4期249-251,共3页 Recent Advances in Ophthalmology
基金 卫生部课题基金!( 96112 2 ) 广东省自然科学基金!( 960 14 5 ) 广东省重点科技攻关项目!( 962 2 0 5 0 0 4)资助
关键词 FK-506 排斥反应 眼表重建术 眼化学伤 FK 506 cornea rejection healing
  • 相关文献

参考文献1

二级参考文献2

共引文献14

同被引文献29

  • 1申济奎,李辰,曾耀英,夏潮涌,葛琪.FK506对大鼠正位穿透性角膜移植排斥反应发生过程中外周血淋巴细胞免疫功能的影响[J].眼科研究,1997,15(2):76-78. 被引量:4
  • 2Akashi T,Nefuji T,Yoshida M,et al.Quantitative determination of tautomeric FK506 by reversed-phase liquid chromatography[J].J Pharm Biomed Anal,1996,14:339-346
  • 3Alak AM,Moy S,Cook M,et al.An HPLC/MS/MS assay for tacrolimus in patient blood samples correlation with results of an ELISA assay [J].J Pharm Biomed Anal,1997,16:7-13
  • 4Kimura H, Ogura Y. Biodegradable polymers for ocular drug delivery. Ophthalmologica, 2001,215:143-155.
  • 5MacFarlane G, Scheller D, Ersfeld DL, et al. Analytical validation of the PRO-Trac Ⅱ ELISA for the determination of tacroliums(FK506) in whole blood. Clin Chem, 1999, 45:1449-1458.
  • 6Venkataramanan R, Warty VS, Zemaitis MA, et al.Biopharmaceutical aspects of FK-506. Transplant Proc, 1987, 19( Suppl 6 ) : 30-35.
  • 7Alak AM, Moy S, Cook M, et al. An HPLC/MS/MS assay for tacrolimus in patient blood samples correlation with results of an ELISA assay. J Pharm Biomed Anal,1997,16:7-13.
  • 8Akashi T, Nefuji T, Yoshida M, et al. Quantitative determination of tautomeric FK506 by reversed-phase liquid chromatography. J Pharm Biomed Anal, 1996,14: 339-346.
  • 9Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Opbthalmol, 1994, 118 : 723-729.
  • 10Sloper CM, Powell BJ, Dua HS. Tacrolinms (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology,2001, 108 : 1838-1844.

引证文献5

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部